Efficacia Di Un Trattamento Con Octreotide Lar in Un Paziente Anziano Affetto Da Carcinoide Cecale

Arnold R. , Trautmann M.E. , Creutzfeldt W. , Benning R. , Neuhaus C. , Jurgensen R. , Stein R. , Schafer H. , Burns C. , Dennler H.J. : Somatostatin analogue and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut, 38: 430–438, 1996.

Di Bartolomeo M. , Bajetta E. , Buzzoni R. , Mariani L. , Carnaghi C. , Somma L. , Zilinibo N. , Di Leo A. : Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer, 77: 402–408, 1996.

Gibril F. , Reynolds J.C. , Chen C.C. , Yu F. , Goebel S.U. , Serrano J. , Doppman J.L. , Jensen R.T. : Specificity of somatostatin receptor scintigraphy: a prospective study and the effects of false positive localizations on management in patients with gastrinomas. J. Nucl. Med., 40: 539–553, 1999.

Kvols L.K. , Moertel C.G. , O'Connell M.J. , Schutt A.J. , Rubin J. , Hahn R.G. : Treatment of the malignant carcinoid: evaluation of a long-acting somatostatin analog. NEJM, 315: 663–666, 1986.

McDermott E.W.M. , Guduric B. , Brennan M.F. : Prognostic variables in patients with gastrointestinal carcinoid tumors. Br. J. Surg., 81: 1007–1009, 1994.

Mignon M. , Jensen R.T. (Eds). Endocrine tumors of the pancreas: recent advances in research and management. S. Karger, Basel, vol. 23, 1–482, 1995.